17.05.2018 07:30
Bewerten
(0)

Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018

DRUCKEN

Regulatory News:

Transgene (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that new clinical data on the oncolytic virus Pexa-Vec will be presented at the American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from 1 to 5 June in Chicago.

These results were obtained from a clinical ("neoadjuvant”) study that evaluated the biological effects of pre-operative intravenous (IV) administration of Pexa-Vec in patients with locally advanced or metastatic cancers, prior to planned surgical resection. University of Leeds (United Kingdom) is the sponsor of this trial that was supported by Transgene.

Poster title: Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity

  • Session Title: Developmental therapeutics - Immunotherapy
  • Poster and abstract number: 3092
  • Date, time, location: June 4, 8:00 AM-11:30 AM, Hall A
  • Presenter: Dr. Alan Anthoney, University of Leeds

The abstract is now available on the ASCO website (http://abstracts.asco.org/).

- End -

Notes to editors

About Pexa-Vec
Pexa-Vec (JX594) is an oncolytic immunotherapeutic based on an oncolytic vaccinia virus armed with a GM-CSF gene that promotes an anti-tumor immune response. Pexa-Vec is designed to selectively target and destroy cancer cells through three different mechanisms of action: selectively destroy cancer cells through the direct lysis (breakdown) of cancer cells through viral replication, reduce the blood supply to tumors through vascular disruption, and stimulate the body’s immune response against cancer cells.
Pexa-Vec is currently being evaluated in a Phase 3 trial in hepatocellular carcinoma (HCC, liver cancer) in combination with sorafenib (current standard of care). Other trials evaluating the oncolytic virus in solid tumors are underway and expected to readout in 2018, including a Phase 2 trial in combination with nivolumab (HCC).
Transgene has exclusive rights to develop and commercialize Pexa-Vec for the treatment of solid tumors in Europe. Its partner SillaJen, Inc. is focused on developing Pexa-Vec for the North American market and has also granted exclusive development and commercial rights to Pexa-Vec in Hong Kong and The People’s Republic of China to Lee’s Pharmaceutical.

About Transgene
Transgene (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s lead clinical-stage programs are: TG4010, a therapeutic vaccine against non-small cell lung cancer, Pexa-Vec, an oncolytic virus against liver cancer, and TG4001, a therapeutic vaccine against HPV-positive head and neck cancers. The Company has several other programs in clinical development, including TG1050 (chronic hepatitis B) and TG6002 (solid tumors).
With its proprietary Invir.IOTM, Transgene builds on its expertise in viral vectors engineering to design a new generation of multifunctional oncolytic viruses.
Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as a joint venture in China. Additional information about Transgene is available at www.transgene.fr.

Follow us on Twitter: @TransgeneSA

Disclaimer
This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. There can be no guarantee that (i) the results of pre-clinical work and prior clinical trials will be predictive of the results of the clinical trials currently underway, (ii) regulatory authorities will agree with the Company’s further development plans for its therapies, or (iii) the Company will find development and commercialization partners for its therapies in a timely manner and on satisfactory terms and conditions, if at all. The occurrence of any of these risks could have a significant negative outcome for the Company’s activities, perspectives, financial situation, results and development.
For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risques”) section of the Document de Référence, available on the AMF website (http://www.amf-france.org) or on Transgene’s website (www.transgene.fr). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.

Nachrichten zu Transgene S.A.

  • Relevant
  • Alle
    1
  • vom Unternehmen
    1
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Transgene S.A.

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
Keine Analysen gefunden.
mehr Analysen

Meistgelesene Transgene News

Keine Nachrichten gefunden.
Weitere Transgene News
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Webinar: Neue Trendfolge-Strategie nach Nicolas Darvas

Simon Betschinger von TraderFox erläutert am 15. Mai einen neuen Trendfolge-Ansatz, der historisch gerechnet erstaunliche 20 % Rendite pro Jahr erzielt hätte.
Mehr erfahren!

Transgene Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX schließt im Minus -- US-Börsen gehen schwächer aus dem Handel -- Trump sagt Gipfel mit Kim Jong Un ab -- Deutsche Bank bestätigt massiven Stellenabbau -- Daimler, Telekom, thyssenkrupp im Fokus

Medigene will durch Kapitalerhöhung Geld für Immuntherapie einnehmen. Facebook: Möglicherweise keine Europäer von Datenskandal betroffen. Diageo will anscheinend US-Marken für bis zu 1 Mrd. Dollar verkaufen. Analystenoptimismus stützt Chemiewerte europaweit. SMA will an Digitalisierung im Energiesektor verdienen.

Die 5 beliebtesten Top-Rankings

Die Top-Flitzer des Genfer Autosalon 2018
Das sind die Highlights
Nach über 40 Jahren: Die Meilensteine der Apple-Geschichte
Was waren die wichtigsten Ereignisse der Apple-Geschichte?
Hier lieber nicht arbeiten
Die gefährlichsten Arbeitgeber in den USA
Diese Aktien hat Warren Buffett im Depot
Einige Änderungen unter den Top-Positionen
Fußball-Weltmeisterschaft 2018So viel Preisgeld erhalten die Teams
Fußball-Weltmeisterschaft 2018So viel Preisgeld erhalten die Teams
mehr Top Rankings

Umfrage

Sollte Bundeskanzlerin Angela Merkel entgegen dem Kurs von US-Präsident Trump am Atom-Abkommen mit dem Iran festhalten?

Online Brokerage über finanzen.net

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von finanzen.net!
Zur klassischen Ansicht wechseln
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Daimler AG710000
CommerzbankCBK100
Apple Inc.865985
Amazon906866
Deutsche Telekom AG555750
Netflix Inc.552484
EVOTEC AG566480
AlibabaA117ME
Steinhoff International N.V.A14XB9
TeslaA1CX3T
Volkswagen (VW) AG Vz.766403
Scout24 AGA12DM8
General Electric Co.851144
Siemens Healthineers AGSHL100